articles
- DELs Inside Cells. 41:225-227. 2020
- Targeting bacterial genomes for natural product discovery. 41:13-26. 2020
- Pharmacological modulation of transcriptional coregulators in cancer. 40:388-402. 2019
- Geroneuroprotectors: effective geroprotectors for the brain. 39:1004-1007. 2018
- Immunopharmacotherapies for treating opioid use disorder. 39:908-911. 2018
- Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases. 39:812-827. 2018
- Protein S-nitrosylation as a therapeutic target for neurodegenerative diseases. 37:73-84. 2016
- Successful strategies to determine high-resolution structures of GPCRs. 37:1055-1069. 2016
- Assay strategies for identification of therapeutic leads that target protein trafficking. 36:498-505. 2015
- Therapeutic targeting of Siglecs using antioody- and glycan-based approaches. 36:645-660. 2015
- Insights into the structure of class B GPCRs. 35:12-22. 2014
- Targeting Th17 cells in autoimmune diseases. 35:493-500. 2014
- Diversity and modularity of g protein-coupled receptor structures. 33:17-27. 2012
- Drug targets: Single-cell transcriptomics hastens unbiased discovery. 33:9-16. 2012
- Gpcr agonist binding revealed by modeling and crystallography. 32:637-643. 2011
- Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. 31:36-45. 2010
- Siglecs as targets for therapy in immune-cell-mediated disease. 30:240-248. 2009
- White matter NMDA receptors: an unexpected new therapeutic target?. 28:561-566. 2007
- Brain reward systems and compulsive drug use. 28:135-141. 2007
- Techniques: Oxidative cross-linking as an emergent tool for the analysis of receptor-mediated signalling events. 26:210-217. 2005
- Epilepsy, cns viral injury and dynorphin. 25:98-104. 2004
- Functional, molecular and pharmacological advances in 5-ht7 receptor research. 25:481-486. 2004
- The ups and downs of addiction: Role of metabotropic glutamate receptors. 25:265-272. 2004
- Nibbling at crf receptor control of feeding and gastrocolonic motility. 24:421-427. 2003
- Being partial to psychostimulant addiction therapy. 23:151-153. 2002
- Structure and function of GABA(c) receptors: a comparison of native versus recombinant receptors. 22:121-132. 2001
- The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. 20:227-230. 1999
- The structure and signalling properties of 5-HT receptors: an endless diversity?. 19:2-4. 1998
- Association of beta(3)-adrenoceptor polymorphism with obesity and diabetes: Current status. 18:449-454. 1997
- NMDA receptors: from genes to channels. 17:348-355. 1996
- Redox state, NMDA receptors and NO-related species. 17:186-187. 1996
- Function and regulation of the beta(3)-adrenoceptor. 17:373-381. 1996
- gp120 and neurotoxicity in vivo. 16:122-122. 1995
- The angiotensin at(2) receptor - searching for signal-transduction pathways and physiological-function. 16:223-225. 1995
- Dopamine-receptor agonists, partial agonists and psychostimulant addiction. 15:374-379. 1994
- The human beta-3-adrenoceptor - the search for a physiological-function. 15:3-7. 1994
- Drugs of abuse - anatomy, pharmacology and function of reward pathways. 13:177-184. 1992
- Functional expression of receptors in microorganisms. 13:95-98. 1992
- Galanin and galanin antagonists: molecular and biochemical perspectives. 13:312-317. 1992
- Mapping determinants of the substrate selectivities of P450 enzymes by site-directed mutagenesis. 13:122-126. 1992
- Modulation mechanisms in cell cell recognition. 6:208-214. 1985
- Presynaptic aspects of the coexistence of classical neurotransmitters and peptides. 6:331-334. 1985
- Biochemical and immunochemical analysis of beta-adrenergic-receptor adenylate-cyclase complexes. 3:282-285. 1982
- Cyclic nucleotides and the nervous system. 3:338-340. 1982